In a groundbreaking study conducted at Georgetown University’s Lombardi Comprehensive Cancer Center, researchers have unveiled a vital cellular mechanism that significantly contributes to the worsened outcomes of breast cancer observed in older individuals. Central to this discovery is the Receptor for Advanced Glycation End-products, or RAGE, a cell surface receptor known for amplifying inflammatory signaling. The study elucidates how RAGE activity escalates with aging and metastatic progression, thereby exacerbating breast cancer spread and mortality.
The significance of this research lies in its focus on aging as a dynamic biological variable influencing cancer metastasis, rather than just a passive risk factor. Barry Hudson, PhD, associate professor of oncology at Lombardi and the study’s lead author, highlighted that traditional cancer research predominantly uses young animal models, which fails to replicate the complex immune and inflammatory alterations that occur in aged hosts. This oversight has limited the understanding of how aging modulates the tumor microenvironment and systemic factors that influence cancer progression and metastasis.
Published in the journal Communications Biology on May 15, 2026, the study takes advantage of a serendipitous opportunity that arose during the COVID-19 pandemic. Laboratory restrictions slowed routine research activities, unintentionally allowing some mouse colonies to age beyond the initial experimental timelines. This extended aging period provided a rare and valuable window to study breast cancer behavior in aged animals, a costly and logistically challenging endeavor under conventional circumstances.
Employing three distinct mouse models of triple-negative breast cancer—a particularly aggressive subtype lacking estrogen, progesterone, and HER2 receptors—the researchers discovered a marked increase in lung metastases in aged mice compared to their younger counterparts. Notably, this increase in secondary tumor spread occurred despite the primary tumor sizes being comparable across age groups. This finding underscores a pivotal shift in metastatic propensity linked directly to aging rather than primary tumor growth kinetics.
Crucially, when the researchers genetically eliminated the RAGE receptor in these mice, the age-associated surge in metastasis was nearly abolished, demonstrating a causal role for RAGE in facilitating cancer dissemination in older hosts. Mechanistic studies revealed that aging elevates the expression of inflammatory ligands such as S100 proteins and HMGB1, which interact with and activate RAGE. These proteins were found both at primary tumor sites and metastatic niches, suggesting a systemic alteration of the tumor microenvironment that favors cancer cell invasion and spread.
This inflammatory milieu engendered by aging not only increases metastatic potential but also remodels immune surveillance, potentially compromising anti-tumor immune responses. The study thereby provides critical insight into why older patients often experience more aggressive disease progression and worse clinical outcomes, independent of the primary tumor characteristics.
Adding translational weight to their findings, the Georgetown team analyzed breast cancer patient data encompassing over 1,000 individuals. Their analysis revealed a strong correlation between elevated expression of the AGER gene, which encodes the RAGE receptor, alongside associated inflammatory gene signatures, and poorer patient prognoses. This clinical association validates the biological relevance of RAGE-mediated pathways in human breast cancer progression.
RAGE is already under investigation as a therapeutic target in various age-related diseases, underscoring its broader significance beyond oncology. Previous preclinical work by Hudson and colleagues demonstrated that TTP488 (azeliragon), a small-molecule RAGE inhibitor, can effectively suppress breast cancer metastasis. Their latest experiments confirmed that TTP488 reduces the invasiveness of tumor cells when exposed to serum from aged mice, indicating that pharmacological blockade of RAGE signaling can counteract the pro-metastatic effects of the aging systemic environment.
Currently, a clinical trial is underway at Lombardi to evaluate the safety and cognitive impact of TTP488 in breast cancer patients undergoing chemotherapy. The drug’s favorable safety record in humans positions it as a promising candidate for further exploration as an adjunctive therapy aimed at limiting metastatic progression and potentially mitigating cancer-related cognitive decline—a common and debilitating comorbidity in older cancer patients.
This study fundamentally shifts the paradigm of cancer biology by emphasizing the critical interplay between host aging, systemic chronic inflammation, and tumor biology. It moves beyond the traditional tumor-centric view, demonstrating that the aged host environment profoundly shapes cancer behavior through mechanisms such as RAGE activation. By highlighting the role of aging as an active modulator rather than a mere background characteristic, this work opens new avenues for therapeutic intervention targeting age-related pathways.
Understanding why cancer metastasizes more aggressively in older patients has direct implications for clinical management and drug development. Since metastasis accounts for the majority of cancer-related deaths, unraveling how aging-related inflammation drives this process may reveal novel targets to inhibit tumor spread. The RAGE receptor and its downstream signaling cascade emerge as compelling candidates in this quest, bridging fundamental aging biology with oncology.
In summary, the findings from the Georgetown team underscore the pressing need to incorporate aging as a critical variable in cancer research models. They also pave the way for innovative treatments that specifically address the vulnerabilities conferred by an aged systemic environment, thereby improving outcomes for a growing population of older breast cancer patients. As life expectancy continues to rise globally, such insights become increasingly vital to tailoring cancer therapies that accommodate the complex biology of aging.
This pivotal research offers hope that targeting inflammatory pathways like RAGE could radically transform the therapeutic landscape of breast cancer metastasis in older adults. Future studies will undoubtedly build on this foundation, exploring combinatorial approaches that integrate RAGE inhibition with existing cancer therapies to enhance efficacy and patient quality of life.
Subject of Research: Animals
Article Title: Aging promotes a RAGE-dependent increase in breast cancer metastasis
News Publication Date: 15-May-2026
Web References: 10.1038/s42003-026-10022-4
Keywords: Breast cancer, Older adults, Aging, RAGE, Metastasis, Inflammation, Triple-negative breast cancer, Cancer progression, Therapeutic target, TTP488, Azeliragon, Immune modulation
Tags: advanced glycation end-products in canceraging as a biological variable in oncologybreast cancer and aging mechanismsCOVID-19 impact on cancer research studiesGeorgetown Lombardi cancer research discoveriesimpact of aging on breast cancer progressioninflammatory signaling in aged cancer patientslimitations of young animal models in cancer researchmetastasis and mortality in elderly breast cancerrole of RAGE receptor in cancer metastasissystemic factors affecting cancer spread with agetumor microenvironment changes with age
